About
Contact
Subscribe
e-Edition

Make Home Page

Dashboard
Logout

- My Account
- Dashboard
- Profile
- Saved items
- Logout

Facebook
Twitter

- Site search

Home
News
Sports
- Local Sports
- National Sports
Business
Opinion
A & E
Life
Features & Magazines
Classifieds
Weather
Obituaries
Last Chance Auction 40% Off

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Roche Holding Div RTS (OP:RHHVF)

412.00 +3.40 (+0.83%)

Streaming Delayed Price Updated: 1:35 PM EDT, May 14, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Roche Holding Div RTS

< Previous 1 2 3 4 5 6 Next >

Roche Agrees To Purchase Part Of COVID-19 Test Player LumiraDx Diagnostics Platform For $295M ↗

January 02, 2024

Friday, LumiraDx Limited (NASDAQ: LMDX) appointed joint administrators for two subsidiaries.

Via Benzinga

Poseida Therapeutics' New Treatment For Multiple Myeloma Shows Early Success In Clinical Trial ↗

December 11, 2023

Poseida Therapeutics Inc (NASDAQ: PSTX) released early efficacy and safety results from its Phase 1 study of P-BCMA-ALLO1, its BCMA-targeted allogeneic, T stem cell memory (TSCM)-rich chimeric antigen...

Via Benzinga

Roche's Combination Therapy Shows Improved Progression Free Survival In Certain Breast Cancer With Mutation ↗

December 05, 2023

Roche Holdings AG (OTC: RHHBY) announced results from the Phase 3 INAVO120 study of the investigational therapy, inavolisib, in combination with palbociclib (Ibrance) and fulvestrant as a potenti

Via Benzinga

Roche Joins Bandwagon To Challenge Novo Nordisk, Eli Lilly For Weight Loss Drugs ↗

December 04, 2023

Roche Holding AG (OTC: RHHBY) has agreed to

Via Benzinga

Sarepta/Roche's Closely Watched Duchenne Gene Therapy Faces More FDA Scrutiny - Stock Tanks ↗

October 31, 2023

Sarepta Therapeutics Inc (NASDAQ: SRPT) released topline results from EMBARK (Study SRP-9001-301) Phase 3 study of Elevidys (delandistrogene moxeparvovec-rokl) in ambulatory boys (those who can walk)...

Via Benzinga

Roche Reports Nine Months Sales Growth Despite Lower Sales From COVID-19 Products ↗

October 19, 2023

Roche Holdings AG's (OTC: RHHBY) nine months

Via Benzinga

What's Going On Cancer Player Monte Rosa Therapeutics Stock Today? ↗

October 17, 2023

Monte Rosa Therapeutics Inc (NASDAQ: GLUE) entered into a strategic collaboration and licensing agreement with Roche Holdings AG (OTC:

Via Benzinga

Is There A Blood Test for Alzheimer's? Progress Underway, But Not Quite Ready ↗

October 11, 2023

Blood tests for diagnosing Alzheimer's disease are eagerly awaited, but it may be a couple of years before they become a routine diagnostic tool. While several blood tests for Alzheimer's diagnosis are...

Via Benzinga

Ionis-Roche Join Forces To Compete In Neurodegenerative Disease Space, Analyst Sees Short-Term Challenges ↗

September 27, 2023

Ionis Pharmaceuticals Inc (NASDAQ: IONS) entered an agreement with Roche Holdings AG (OTC: RHHBY

Via Benzinga

Biden Administration Restarts Distribution Of Free At Home COVID-19 Tests, After Suspending For Year ↗

September 21, 2023

In response to the escalating spread of the virus nationwide, the Biden administration declared that it would recommence offering free at-home COVID tests to American households starting next Monday.

Via Benzinga

Hypertension Impacts 1.2B People - Alnylam's Gene Silencing Drug Candidate Hits the Mark in Phase 2 Study, Offering Hope ↗

September 07, 2023

Alnylam Pharmaceuticals Inc's (NASDAQ: ALNY) KARDIA-1 Phase 2 study of zilebesiran, an investigational RNAi therapeutic targeting liver-expressed angiotensinogen (AGT) for hypertension,

Via Benzinga

Roche's Approved Lung Cancer Drug Beats Chemo In Rare Type Of Lung Cancer ↗

September 01, 2023

Roche Holdings AG (OTC: RHHBY) announced that the Phase 3 ALINA study evaluating Alecensa (alectinib), compared with platinum-based chemotherapy, met its primary endpoint of disease-free survival (DFS)...

Via Benzinga

Cancer Treatment In 7 Minutes: UK's Health Service To Rollout Roche's Tencentriq Injection Cutting Treatment Time ↗

August 30, 2023

The U.K.'s Medicines and Healthcare products Regulatory Agency (MHRA) has granted approval to the National Health Service (NHS) to impleme

Via Benzinga

Who Are Other Players Gaining From Roche's Accidental Lung Cancer Data Update ↗

August 23, 2023

Earlier today, Roche Holdings AG (OTC: RHHBY) announced that it had been made aware of inadvertent disclosure of the second interim analysis of Phase 3 SKYSCRAPER-01 study, evaluating tiragolumab plus...

Via Benzinga

Roche's Accidental Lung Cancer Trial Data Leak: Shows Encouraging Early Data From Combination Therapy Study ↗

August 23, 2023

Roche Holdings AG (OTC: RHHBY) announced that it had been made aware of inadvertent disclosure of t

Via Benzinga

Third Time Lucky: Exelixis' Cabozantinib Combo Therapy Aces Pivotal Study In Prostate Cancer Patients ↗

August 21, 2023

Roche Holdings AG (OTC: RHHBY), Exelixis Inc (NASDAQ: EXEL), and Ipsen&nbs

Via Benzinga

Johnson & Johnson, Other Pharma Makers Anticipate Reformulated Injectable Drugs May Exclude Price Negotiations ↗

July 28, 2023

Cancer drug manufacturers, including Johnson & Johnson (NYSE: JNJ), anticipate that injectable versions of some popular treatments will not be included in U.S.

Via Benzinga

Novo Nordisk's Obesity Drug Saxenda Not Included In WHO's Essential Drug List ↗

July 26, 2023

The World Health Organization (WHO) published the new editions of the Model Lists of Essential Medicines (EML) and Essen

Via Benzinga

Alnylam Inks Co-Development, Co-Commercialization Pact With Roche For Hypertension Therapy ↗

July 24, 2023

Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) entered a strategic agreement with Roche Holdings AG (OTC: RHHBY) to

Via Benzinga

Republican Presidential Candidate Vivek Ramaswamy Founded Roivant In Discussions With Roche For $7B Stomach Disease(s) Drug Deal ↗

July 14, 2023

Roivant Sciences Ltd (NASDAQ: ROIV), a biotech company founded by Vivek Ramaswamy, a Republican presidential candidate, is reportedly in discussions with Roche Holdings AG (OTC: RHHBY)

Via Benzinga

Roche's Approved Multiple Sclerosis Drug: Subcutaneous Injection At Par With Intravenous Infusion ↗

July 13, 2023

Roche Holdings AG's (OTC: RHHBY) Phase 3 OCARINA II trial evaluating Ocrevus (ocrelizumab) as a twice-a-year 10-minute subcutaneous injection met its primary and secondary endpoints in patients with...

Via Benzinga

Roche's Bispecific Antibody With Fixed-Duration Treatment Scores FDA Approval For Type Of Lymphoma ↗

June 16, 2023

The FDA approved Roche Holding AG's (OTC: RHHBY) Columvi (glofitamab-gxbm) for relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) not otherwise specified or large B-cell lymphoma (LBCL)...

Via Benzinga

New Data Show Roche's Self-Administered Blood Disorder Candidate Achieves Disease Control ↗

June 09, 2023

Roche Group Holdings AG's (OTC: RHHBY) data from the global phase 3 COMMODORE 1 and 2 studies e

Via Benzinga

Roche's Investigational Drug For Relapsing Multiple Sclerosis Reduces Brain Lesions, Data Shows ↗

May 17, 2023

Roche Holdings AG's (OTC: RHHBY) Phase 2 FENopta study of oral fenebrutinib for relapsing forms of multiple sclerosis (RMS)

Via Benzinga

Roche's Q1 Highlights: Increased Uptake Of Eye Disease Drug Cushions Sales Decline ↗

April 26, 2023

Roche Holdings AG's (OTC: RHHBY) first-quarter sales dropped 7% Y/Y (down 3% at constant currency)

Via Benzinga

FDA Approves Roche's Polivy Combo Therapy For Untreated Patients With Diffuse Large B-Cell Lymphoma ↗

April 20, 2023

Via Benzinga

EXCLUSIVE: FDA Grants Expedited Review Status To SAB Biotherapeutics' Influenza Antibody ↗

April 13, 2023

The FDA has granted Fast Track designation for SAB Biotherapeutics' (NASDAQ: SABS) SAB-176, an investigational therapeutic for Type A and Type B influenza illness in high-risk patients, including those...

Via Benzinga

New Four Year Data For Roche's Evrysdi Reinforces Long-Term Efficacy, Safety Profile In Muscular Atrophy Patients ↗

March 20, 2023

Via Benzinga

FDA Casts Doubts Over Roche's Polivy Label Expansion For Untreated Lymphoma Setting ↗

March 09, 2023

Via Benzinga

Roche, Exelixis Report Second Flop Out Of Three Trials Evaluating Cabozantinib/Atezolizumab Combo ↗

March 03, 2023

Via Benzinga

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Sections

News
Sports
Opinion
Photo Galleries
Videos
Local Events
Classifieds
Obituaries

Services

About
Contact
Personnel
Advertise
Subscription Services
Promote Your Event
Dealer Locations
Email Alerts
Submission Forms

Contact Information

chroniclejournal.com
75 S. Cumberland Street
Thunder Bay, ON P7B 1A3
Phone: 807 343 6200
Email: circulation@chroniclejournal.com

Facebook
Twitter

Browser Compatibility

Your browser is out of date and potentially vulnerable to security risks.
We recommend switching to one of the following browsers:

Microsoft Edge Google Chrome Firefox

Roche Holding Div RTS (OP:RHHVF)

Headline News about Roche Holding Div RTS

Sections

Services

Contact Information

Follow Us